Impact Events
More| Date | Lead Company | Event | Type | Approval Change | Approval Likelihood |
|---|---|---|---|---|---|
| 2/2/26 | Skye Bioscience (SKYE) | nimacimab for Obesity | Subscribers Only | Subscribers Only | Subscribers Only |
| 2/1/26 | Pharming (PHAR) | Joenja for Activated PI3K Delta Syndrome (APDS) | Subscribers Only | Subscribers Only | Subscribers Only |
| 1/29/26 | Delta-Fly (4598) | DFP-10917 for Acute Myelogenous Leukemia (AML) | Subscribers Only | Subscribers Only | Subscribers Only |
| 1/27/26 | Sarepta Therapeutics (SRPT) | Elevidys for Duchenne Muscular Dystrophy (DMD) | Subscribers Only | Subscribers Only | Subscribers Only |
| 1/23/26 | Trevi (TRVI) | Haduvio for Chronic Cough | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
More| Expected Date Range | Lead Company | Drug | Expected Catalyst |
|---|---|---|---|
| 06/25/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 06/25/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 06/26/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 09/08/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 09/17/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |